Axsome Therapeutics, Inc.: management transactions · United States · SEC (Form 4)

About Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on central nervous system (CNS) disorders, a therapeutic area that remains both clinically challenging and commercially attractive because of persistent unmet medical need. Founded in 2012, Axsome built its strategy around developing and commercializing differentiated treatments for psychiatric and neurological conditions. The company is listed on the NASDAQ under the ticker AXSM, and its corporate headquarters is in New York, United States. ([stockanalysis.com](https://stockanalysis.com/stocks/axsm/company/?utm_source=openai)) Axsome’s business model now combines marketed products with a late-stage CNS pipeline. Its core commercial assets include AUVELITY, approved for major depressive disorder in adults; SUNOSI, used to treat excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea; and SYMBRAVO, which received FDA approval in January 2025 for the acute treatment of migraine with or without aura in adults. The company also highlights its proprietary MoSEIC technology for selected formulations and positions its portfolio around multi-mechanistic approaches intended to address complex CNS symptoms. ([stockanalysis.com](https://stockanalysis.com/stocks/axsm/company/?utm_source=openai)) From a competitive standpoint, Axsome operates in highly contested markets dominated by large pharmaceutical companies as well as neuroscience-focused specialists. Its differentiation rests on product innovation, clinical execution, and the gradual expansion of its marketed portfolio. Axsome describes itself as targeting treatment gaps in conditions where existing options are limited, which can support a premium positioning if physician adoption and payer access continue to improve. ([axsome.com](https://www.axsome.com/about-axsome/)) Geographically, the company remains primarily U.S.-centric. Its commercial footprint, revenue generation, and major regulatory interactions are largely tied to the United States, although some SEC filings reference entities and agreements related to non-U.S. rights or structures. For investors, the practical operating base is still overwhelmingly American. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1579428/000095017025058788/axsm_fy2024_ars.pdf)) Recent developments are important for the investment case. In January 2025, the FDA approved SYMBRAVO, and Axsome said it was preparing a commercial launch beginning in June 2025. The company also reported progress on AXS-05 in Alzheimer’s disease agitation, including positive pre-NDA interactions with the FDA in March 2025 and plans for a supplemental NDA filing. In parallel, Axsome has continued to expand its sales force and strengthen its commercial infrastructure around AUVELITY and SUNOSI. Taken together, these milestones reinforce Axsome’s profile as a NASDAQ-listed U.S. neuroscience growth company transitioning from development-heavy execution toward a more diversified commercial platform. ([axsometherapeuticsinc.gcs-web.com](https://axsometherapeuticsinc.gcs-web.com/node/12031/pdf))